Hada T, Fukui K, Ohno M, Akamatsu S, Yazawa S, Enomoto K, Yamaguchi K, Matsuda Y, Amuro Y, Yamanaka N
Third Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-Cho Nishinomiya, Japan.
Glycoconj J. 1995 Oct;12(5):627-31. doi: 10.1007/BF00731257.
Alpha (1 --> 3)-L-fucosyltransferase (alpha 1,3FT) activity was determined in plasma of patients with chronic liver diseases, namely, chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC), The plasma alpha 1,3FT activity was significantly higher (p < 0.01) in chronic liver diseases than that in normal controls. The enzyme activity in plasma of patients with HCC was also significantly higher than that in LC (p < 0.05) or that in CH (p < 0.01). However, no significant difference was observed in the enzyme activity between LC and CH. Plasma alpha 1,3FT activity in patients with HCC was not significantly changed before and after transcatheter arterial embolization. In addition, the enzyme activity in the homogenate of the cirrhotic liver tissue was higher than that in the preparation of the hepatoma tissue in the same patient. These results suggest that the increased plasma alpha 1,3FT activity in patients with HCC reflects mainly the enzyme activity of cirrhotic liver tissue, not that of hepatoma tissue. The significance of the elevated levels of plasma alpha 1,3FT and its decreased hepatoma tissue activity in patients with HCC, compared with that in LC, remains to be clarified.
测定了慢性肝病患者，即慢性肝炎（CH）、肝硬化（LC）和肝细胞癌（HCC）患者血浆中的α（1→3）-L-岩藻糖基转移酶（α1,3FT）活性。慢性肝病患者血浆中的α1,3FT活性显著高于正常对照组（p<0.01）。HCC患者血浆中的酶活性也显著高于LC患者（p<0.05）或CH患者（p<0.01）。然而，LC和CH患者之间的酶活性未观察到显著差异。HCC患者经导管动脉栓塞前后血浆α1,3FT活性无显著变化。此外，同一患者肝硬化肝组织匀浆中的酶活性高于肝癌组织匀浆中的酶活性。这些结果表明，HCC患者血浆α1,3FT活性升高主要反映肝硬化肝组织的酶活性，而非肝癌组织的酶活性。与LC患者相比，HCC患者血浆α1,3FT水平升高及其肝癌组织活性降低的意义仍有待阐明。
